#1Corporate Presentation 6th September 2023 Nasdaq: NMRD ~ NEMAURA MEDICAL#2Forward-Looking Statements This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura's short-term and long-term growth strategies, can sometimes be identified by use of terms such as "intend," "expect," "plan," "estimate," "future," "strive," and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura's filings with the Securities and Exchange Commission (the "Commission"), including the risks identified under the section captioned "Risk Factors" in Nemaura's Annual Report on Form 10-K filed with the Commission on June 29, 2022 as the same may be updated from time to time. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.#3What is the market space Nemaura is trying to address?#4A recent article in Forbes¹ states: Over 11% of the US population is known to be diabetic; that translates into 37,300,000 people. Compounding the problem are approximately estimated 8,500,000 people who have diabetes but remain undiagnosed. People with diagnosed diabetes incur average medical expenditures of $16,752 per year, of which about $9,601 is attributed to diabetes. The CDC estimates that 96,000,000 adults (38% of the population) in the United States are pre-diabetic and 80% of them do not know that they have it! Forbes#5IM To address this, we developed a Non-invasive daily wear continuous Glucose sensor targeting: Clinical Market: Type 2 diabetes: >60 million people in Europe² Consumer market: Pre-diabetes and Obesity: >90 million people¹ in USA [This market is currently deemed to be the largest opportunity for Nemaura]#6B Good morning, Samantha Time 09:03 Today 6.2 sugor BEAT ↑ 2 10.6 94 6.5 6.2 Our Goals and What we have delivered so far.. TARGET: Develop sugarBEAT® a wearable device form factor (see image on left). STATUS: Complete TARGET: Complete Pivotal clinical program and obtain CE approval STATUS: Complete TARGET: Receive first purchase order for sugar BEATⓇ STATUS: Complete - 200K sensors/5K devices TARGET: Obtain SFDA (Saudi Arabia Food and Drug Authority) approval STATUS: Complete (August 2023) TARGET: Receive Purchase orders for Middle East / MENA STATUS: Complete - 1.7m sensor/17K devices. Supply timelines being determined#7B Good morning, Samantha Time 09:03 Today 6.2 suporEAT ↑ 2 10.6 94 6.5 6.2 Our Goals and What we have delivered so far.. TARGET: Develop a a Metabolic health and diabetes management program leveraging off sensor platform STATUS: Complete: BEATdiabetes.life & Miboko.com TARGET: Develop launch plans for BEAT®diabetes and Miboko. STATUS: Entered into preliminary agreement with Eversana, who have a 6000+ strong team and the required infrastructure to help take Nemaura's programs through to large scale deployment. TARGET: Obtain FDA approval for sugarBEATⓇ STATUS: BIMO and GMP audits undertaken by FDA - further updates to be provided in due course.#8B Good morning, Samantha Time 09:03 Today 6.2 sugor BEAT ↑ 2 10.6 94 6.5 6.2 Future targets.. TARGET: Obtain FDA approval for sugarBEATⓇ TARGET: Scale-up manufacture to support sales in UK, Europe & and Middle East through licensees TARGET: Build market share in USA with employers and insurers, for the BEAT diabetes and Miboko (non-medical) programs. Scaled-up Pilot programs in June 2023. TARGET: Launch sugarBEAT® 'Direct-to-Consumer' in all major territories accepting CE approval as part of product registration; Discussions in multiple territories ongoing TARGET: Commercial exploitation of the metabolic health and wellbeing market using the sensors, initially targeting over 87 million people in the USA with pre- diabetes¹#9sugarBEATⓇ Example of Volunteer data compared with BGM and Invasive CGM 25 20 15 10 5 0 00:60 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00 23:00 00:00 Blue: Finger Prick BGM (Blood glucose meter) Red: Invasive CGM 50000 45000 40000 35000 30000 25000 20000 15000 09:48:01 10:33:01 TO:8T:IT TO:EOZT 12:48:01 13:33:01 14:23:01 15:08:01 15:53:01 16:38:01 17:23:01 18:08:01 18:53:01 19:38:01 20:28:01 21:13:01 21:58:01 TO:ED:ZZ sugarBEATⓇ Raw data presented (prior to algorithmic conversion, demonstrating tight correlation) 23:28:01#10sugarBEATⓇ Example of Volunteer data (Non-diabetic) 23:59 W History 25 20 15 10 ( Wed, 07 Sept 2022 Time 20:10 13:55 15:55 17:55 MSW VIEW AGP 7.5 mmol/L 19:55 CREATE REPORTS all 86% 21:55 23:55#11Product Positioning Medical: sell sugarBEATⓇ sensors Diabetes Management (non-medical): BEATdiabetes program and sensors Consumer health and wellbeing: Miboko sensor and app#12Product Positioning - Medical sugarBEATⓇ CGM sales through Licensee(s) - no further marketing spend required on Nemaura's part thus minimizing cost of sales. Support UK Licensee: Licensee engaged in studies designed to support reimbursement from the UK government. Middle East: SFDA Approval achieved. Orders for 1.7 million sensors and 17,000 transmitters received and undergoing scheduling of delivery upon finalization of launch plans.#13Product Positioning - Type 2 Type 2 Diabetes management and reversal using BEATdiabetes program and sensors Signed term sheet with Eversana who have a 6000+ salesforce, to sell the program B to B. Aiming for reimbursement for T2 diabetes management#14Product Positioning - Consumer Metabolic health and wellbeing: Miboko app • Phase 1 Beta running Piloting with NHS in UK Positive feedback thus far Aiming for reimbursement for preventative medicine/high risk persons Targeting partnership/collaborations in 2023#15Marketing Strategy - Plug-in Recent feedback suggests there is a significant business case to offer the Metabolic health program (from Miboko), and the proBEAT sensor and auto- generated progress report as plug-ins to existing diabetes management and metabolic health programs. In the USA alone there are over 2000³ such organisations Nemaura can target. This would further minimize the need for infrastructure and associated costs to Nemaura.#16Competitive landscape Noom: Over 50 million Subscribers, >$400m Revenues in 20205 Miboko USP: A holistic Metabolic health approach to weight loss and better health supported using our proprietary wearable sensor that gives an insight in to what's really happening inside the body#17sugarBEATⓇ Regulatory Status ■ ● CE Approved Class 2b Medical Device in Europe FDA PMA submitted and in review FDA Bio-monitoring Division (BIMO) Audit conducted in December 2021 at Nemaura's UK facility. A single 483 observation was issued. Company submitted a full and complete response to FDA in January 2022. • FDA Pre-market inspection covering FDA's Quality System/Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820) completed in Q2 2022. Full response sent and company continues dialogue in relation to the application. Further updates to be provided in due course.#18Future Product Opportunities Leveraging the BEATⓇ Technology A rich portfolio of additional products to complement existing offering and contribute to increased revenues 01 CONTINUOUS LACTATE MONITORING Assists in threshold maximization in performance athletes Early identification of tissue hypoperfusion or shock for aggressive early resuscitation of critically ill patients to improve the their chances of survival 02 BODY TEMPERATURE MONITORING Gives a more accurate and large data set. For monitoring viral infections and lower limb blood circulation tracking the effectiveness of drugs Wearable temperature sensors market is expected to register a CAGR of 8.3% during the forecast period 2021-20266#19Future Product Opportunities Leveraging the BEATⓇ Technology 03 ALCOHOL MONITORING Support personal health goals and provide warnings prior to driving. Provide physicians with individual's drinking habits. Prevention of progression-to-alcohol-related disease 04 DRUG MONITORING Monitoring the impact of drugs and personalized treatment plan for patients. Global therapeutic drug monitoring device market estimated to reach $3.37B by 20247#20Intellectual Property IP consists of Filed Patents and substantial know-how#21Summary Revenue generating and ramp-up in revenues anticipated through product and subscription service sales and potential new partnerships First mover advantage with the non-invasive sensor platform ▪ Simple subscription-based revenue generation models. Highly Scalable business model with potential for rapid growth and product introductions in the consumer space (non-regulated market) as well as in the clinical space. ■#22References do-we-treat-it/?sh=114c799b65be NEMAURA 1. https://www.forbes.com/sites/stephenbrozak/2022/11/07/diabetesthe-pandemic-is-here-how- 2. 3. https://www.cdc.gov/diabetes/library/reports/reportcard/national-dpp.html https://www.who.int/europe/health-topics/diabetes#tab=tab 1 MEDICAL